PLGA(75:25)(poly(lactic-co-glycolic acid)) |
| Catalog No.GC30049 |
Le PLGA (75:25) (poly (acide lactique-co-glycolique)) est un support d'administration contrÔlée de médicaments À faible toxicité, biocompatible et biodégradable, qui peut obtenir une libération lente dans l'organisme.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 34346-01-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PLGA(poly (lactic-co-glycolic acid)) is made by random polymerization of two monomers: lactic acid and glycolic acid. It is a degradable functional polymer organic compound with good biocompatibility, non-toxic, and good cystforming and film forming properties. It is widely used in pharmaceutical, medical engineering materials and modern industrial fields[1,2].
PLGA@Icaritin nanoparticles (NPs) dramatically suppressed cell growth, induced Lactic dehydrogenase (LDH) leakage, arrested more GC cells at G2 phase, and inhibited the invasion and metastasis of GC cells, compared to free icaritin. In addition, PLGA@Icaritin could help generate dozens of reactive oxygen species (ROS) within GC cells, following by significant mitochondrial membrane potentials (MMPs) loss and excessive production of oxidative-mitochondrial DNA (Ox-mitoDNA)[3].
References:
[1]. Gentile P, Chiono V, et,al. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014 Feb 28;15(3):3640-59. doi: 10.3390/ijms15033640. PMID: 24590126; PMCID: PMC3975359.
[2]. Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, et,al.PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517-35. doi: 10.7314/apjcp.2014.15.2.517. PMID: 24568455.
[3]. Xiao Y, Yao W, et,al.Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer. Drug Deliv. 2022 Dec;29(1):1712-1725. doi: 10.1080/10717544.2022.2079769. PMID: 35635307; PMCID: PMC9176696.
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *